Initial experience with technetium-99m HM-PAO brain SPECT.
Technetium-99m hexamethylpropyleneamineoxime ([99mTc]HM-PAO) brain single photon emission computed tomography (SPECT) was performed with a dual head rotating scintillation camera. Normal tracer distribution and side/side differences of counting rates were obtained in 11 healthy volunteers. Almost stable gray/white matter ratios were found (1.97-2.1) in one normal subject during 2 hr after tracer administration. Eighty-three investigated patients had the following diagnoses (in parentheses is percent of positive findings in each group): cerebral vascular disease 18 (94.4%), epilepsy 23 (82.6%), extrapyramidal disorders 8 (100%), dementia 12 (100%), headache 11 (63.6%), psychiatric disorders 11 (27.3%). In addition, SPECT was performed in 28 male volunteers during motor or visual imagery tasks and a significant increase (p = 0.035) of relative tracer deposition was observed in the left inferior occipital region during visual imagery when compared with motor imagery. The results indicate that [99mTc]HM-PAO SPECT is valuable for demonstrating pathologic and physiologic changes of the brain.
D000328:Adult; D000368:Aged; D001480:Basal Ganglia Diseases / Q000000981:diagnostic imaging; D001921:Brain / Q000000981:diagnostic imaging*; D002560:Cerebrovascular Circulation; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging; D003704:Dementia / Q000503:physiopathology; D004827:Epilepsy / Q000000981:diagnostic imaging; D005260:Female; D006261:Headache / Q000000981:diagnostic imaging; D006801:Humans; D007092:Imagination / Q000502:physiology; D008297:Male; D001523:Mental Disorders / Q000503:physiopathology; D008875:Middle Aged; D009942:Organometallic Compounds; D010091:Oximes; D013667:Technetium; D019690:Technetium Tc 99m Exametazime; D014055:Tomography, Emission-Computed
D009942:Organometallic Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime; D013667:Technetium